Alcoholic liver disease secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Irfan Dotani (talk | contribs) No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Alcoholic liver disease}} | {{Alcoholic liver disease}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{MKA}} | ||
==Overview== | ==Overview== | ||
Line 7: | Line 7: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
*Effective measures for the secondary prevention of alcoholic liver disease include:<ref name="pmid19489992">{{cite journal |vauthors=Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N |title=The effectiveness of brief alcohol interventions in primary care settings: a systematic review |journal=Drug Alcohol Rev |volume=28 |issue=3 |pages=301–23 |year=2009 |pmid=19489992 |doi=10.1111/j.1465-3362.2009.00071.x |url=}}</ref><ref name="pmid8925349">{{cite journal |vauthors=Moos RH, King MJ, Patterson MA |title=Outcomes of residential treatment of substance abuse in hospital- and community-based programs |journal=Psychiatr Serv |volume=47 |issue=1 |pages=68–74 |year=1996 |pmid=8925349 |doi=10.1176/ps.47.1.68 |url=}}</ref><ref name="pmid15200577">{{cite journal |vauthors=Bouza C, Angeles M, Magro A, Muñoz A, Amate JM |title=Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review |journal=Addiction |volume=99 |issue=7 |pages=811–28 |year=2004 |pmid=15200577 |doi=10.1111/j.1360-0443.2004.00763.x |url=}}</ref><ref name="pmid10208148">{{cite journal |vauthors=Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT |title=Pharmacological treatment of alcohol dependence: a review of the evidence |journal=JAMA |volume=281 |issue=14 |pages=1318–25 |year=1999 |pmid=10208148 |doi= |url=}}</ref><ref name="pmid19630744">{{cite journal |vauthors=Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM |title=Review of topiramate: an antiepileptic for the treatment of alcohol dependence |journal=Curr Drug Abuse Rev |volume=2 |issue=2 |pages=135–42 |year=2009 |pmid=19630744 |doi= |url=}}</ref><ref name="pmid18068515">{{cite journal |vauthors=Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G |title=Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study |journal=Lancet |volume=370 |issue=9603 |pages=1915–22 |year=2007 |pmid=18068515 |doi=10.1016/S0140-6736(07)61814-5 |url=}}</ref><ref name="pmid7672043">{{cite journal |vauthors=Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F |title=The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease |journal=Eur. J. Epidemiol. |volume=10 |issue=6 |pages=657–64 |year=1994 |pmid=7672043 |doi= |url=}}</ref><ref name="pmid1476147">{{cite journal |vauthors=Klatsky AL, Armstrong MA |title=Alcohol, smoking, coffee, and cirrhosis |journal=Am. J. Epidemiol. |volume=136 |issue=10 |pages=1248–57 |year=1992 |pmid=1476147 |doi= |url=}}</ref><ref name="pmid8985274">{{cite journal |vauthors=Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC |title=Excess weight risk factor for alcoholic liver disease |journal=Hepatology |volume=25 |issue=1 |pages=108–11 |year=1997 |pmid=8985274 |doi=10.1002/hep.510250120 |url=}}</ref> | |||
**Naltrexone or acamprosate to prevent relapse | |||
**Disulfiram and topiramate for decreasing craving and withdrawal symptoms | |||
**Smoking cessation and weight loss where indicated | |||
** | |||
==References== | ==References== |
Revision as of 17:12, 29 December 2017
Alcoholic liver disease Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Alcoholic liver disease secondary prevention On the Web |
American Roentgen Ray Society Images of Alcoholic liver disease secondary prevention |
Risk calculators and risk factors for Alcoholic liver disease secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
One should discuss the alcohol intake with the doctor. The doctor can counsel about how much alcohol is safe to drink.
Secondary Prevention
- Effective measures for the secondary prevention of alcoholic liver disease include:[1][2][3][4][5][6][7][8][9]
- Naltrexone or acamprosate to prevent relapse
- Disulfiram and topiramate for decreasing craving and withdrawal symptoms
- Smoking cessation and weight loss where indicated
References
- ↑ Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N (2009). "The effectiveness of brief alcohol interventions in primary care settings: a systematic review". Drug Alcohol Rev. 28 (3): 301–23. doi:10.1111/j.1465-3362.2009.00071.x. PMID 19489992.
- ↑ Moos RH, King MJ, Patterson MA (1996). "Outcomes of residential treatment of substance abuse in hospital- and community-based programs". Psychiatr Serv. 47 (1): 68–74. doi:10.1176/ps.47.1.68. PMID 8925349.
- ↑ Bouza C, Angeles M, Magro A, Muñoz A, Amate JM (2004). "Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review". Addiction. 99 (7): 811–28. doi:10.1111/j.1360-0443.2004.00763.x. PMID 15200577.
- ↑ Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999). "Pharmacological treatment of alcohol dependence: a review of the evidence". JAMA. 281 (14): 1318–25. PMID 10208148.
- ↑ Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM (2009). "Review of topiramate: an antiepileptic for the treatment of alcohol dependence". Curr Drug Abuse Rev. 2 (2): 135–42. PMID 19630744.
- ↑ Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007). "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study". Lancet. 370 (9603): 1915–22. doi:10.1016/S0140-6736(07)61814-5. PMID 18068515.
- ↑ Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F (1994). "The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease". Eur. J. Epidemiol. 10 (6): 657–64. PMID 7672043.
- ↑ Klatsky AL, Armstrong MA (1992). "Alcohol, smoking, coffee, and cirrhosis". Am. J. Epidemiol. 136 (10): 1248–57. PMID 1476147.
- ↑ Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC (1997). "Excess weight risk factor for alcoholic liver disease". Hepatology. 25 (1): 108–11. doi:10.1002/hep.510250120. PMID 8985274.